Marc Zuckerman, MD
Gastroenterology · El Paso, TXNPI 1245268168
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,900 of the $40,900 with a category attached, or 73.1%. Phathom Pharmaceuticals, Inc. accounts for 67.3% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2024 at $26,177 and has fallen 77.6% since, to $5,851 in 2025. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $148.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$28K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$5K
- Intercept Pharmaceuticals, Inc.$2K
- AbbVie$1K
- Gilead$1K
- Takeda Pharmaceuticals U.S.A., Inc.$687
- plus $3K from 19 others
Across 13 payments — averaging $2812.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$37K
What the payments were for
- Speaking & faculty fees$29,90073%
- Travel & lodging$8692%
- Food & beverage$10,11425%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 40 | $27,512 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $4,859 |
| Intercept Pharmaceuticals, Inc. | 8 | $1,864 |
| AbbVie(2 entities) | 58 | $1,418 |
| Gilead | 18 | $1,183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $687 |
| Madrigal Pharmaceuticals | 8 | $684 |
| Johnson & Johnson | 31 | $500 |
| Ardelyx, Inc. | 12 | $465 |
| Pfizer | 9 | $353 |
| Sanofi | 3 | $189 |
| Medtronic | 3 | $180 |
| Enterra Medical, Inc. | 1 | $154 |
| Cook Medical LLC | 1 | $148 |
| Regeneron | 2 | $141 |
| Regeneron Healthcare Solutions, Inc. | 3 | $138 |
| Covidien LP | 2 | $113 |
| Exact Sciences | 1 | $101 |
| Olympus America Inc. | 3 | $95 |
| Boston Scientific | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Ambu Inc. | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Apollo Endosurgery US Inc | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,900 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 39 | $121,414 |
| Omeprazole | 31 | $876 |
| Esomeprazole Magnesium | 17 | $573 |
| Dicyclomine Hcl | 12 | $481 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 36 | $473 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 30 | $468 |
| Propranolol Hcl | 19 | $253 |
| Spironolactone | 17 | $221 |
| Pantoprazole Sodium | 39 | $210 |
| Tramadol Hcl | 12 | $141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $4,859 | $121,41439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in El Paso
- John FordtranDallas$9.9M
- Michael BrownDallas$5.5M
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Anish PatelFort Sam Houston$1.3M
- Timothy RitterSouthlake$961K
- Parvez MantryDallas$958K
- Nadege GunnWaco$933K
- Brooks CashHouston$867K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.